BackKaryopharm Therapeutics Overview

Karyopharm Therapeutics Research & Development

Research & Development expenses for KPTI.

Quarterly R&D Expenses

$33.78M
↓ 2.41% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$124.78M
↓ 12.33% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin